Artivion (NYSE:AORT) Shares Gap Down – Should You Sell?

Artivion, Inc. (NYSE:AORT)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $36.62, but opened at $33.60. Artivion shares last traded at $33.1650, with a volume of 15,025 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AORT. Stifel Nicolaus set a $55.00 target price on Artivion in a research report on Thursday, March 5th. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Canaccord Genuity Group decreased their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $58.00 target price on shares of Artivion in a research note on Monday, February 2nd. Finally, Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $50.47.

Artivion Stock Down 0.1%

The company has a market capitalization of $1.66 billion, a P/E ratio of 170.71 and a beta of 1.63. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The firm has a fifty day simple moving average of $37.71 and a 200-day simple moving average of $41.86.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. The business’s revenue for the quarter was up 19.2% compared to the same quarter last year. On average, equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Insider Activity at Artivion

In related news, CEO James P. Mackin sold 20,962 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $37.59, for a total transaction of $787,961.58. Following the sale, the chief executive officer directly owned 780,031 shares in the company, valued at $29,321,365.29. This trade represents a 2.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 8,962 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the sale, the senior vice president directly owned 185,095 shares in the company, valued at $7,033,610. This represents a 4.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 133,043 shares of company stock worth $4,977,158. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Artivion

A number of large investors have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd lifted its holdings in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion during the third quarter worth about $27,000. Rockefeller Capital Management L.P. grew its holdings in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after buying an additional 399 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares in the last quarter. Finally, USA Financial Formulas raised its position in Artivion by 163.5% in the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after buying an additional 703 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.